Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05986669

Safety and Effectiveness of DSP Dental Implant Systems: Prospective Study Multicenter Involving Real-world Data

Studies on facial trauma are essential to establish an appropriate treatment approach, assess the ability to restore functions and seek ways of prevention. Among craniofacial injuries, fractures of the zygomatic complex are the most frequent, occurring in 25-30% of cases. Statistical analysis shows that traffic collisions (41%), domestic accidents (23%) and sports accidents (18%) are the main causes. Dental implants have emerged as a rehabilitative alternative for these patients, being considered the first choice for individuals who have lost all or part of their dental arch. In addition to providing a better quality of life, it reconstitutes masticatory function, self-esteem and phonetics. Understanding the importance of evaluating the performance of dental implants and considering the responsibility for the health of patients, there was a need to evaluate the effectiveness and safety of the Standard Internal Hexagon Implant System (HIS), Large Internal Hexagon (HIL), Flexcone (FC) , Mini Flexcone (FCM) and Morse Internal Hexagon, from DSP. In this prospective study, 1053 implants will be included. To be eligible, patients can be of both sexes, be 18 years of age or older, any race and gender, have partial or total tooth loss, present good local and general health conditions and psychological disposition to undergo common oral surgery procedures. under local anesthesia and healthy edentulous region as they will be subsequently submitted to surgical procedures using the DSP Implant System. Electronic data collection and management will be performed using the REDCap software, with categorical variables being described as absolute and relative frequencies and continuous ones being tested for normality using the Shapiro-Wilk test. Osseointegration percentages between 30 days and 6 months will also be calculated. Other efficacy outcomes and incidence of adverse events will be estimated with 95% confidence intervals. As a result, from the strengthening of product evaluation actions, it is expected to demonstrate that the implant has a good safety and efficacy profile to be offered to the population.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

DSP Oral Clinica, Campo Largo, Paraná, Brazil

Loading trial locations.

About this study

The study was designed as a prospective observational clinical record. This protocol will be submitted to the Ethics Committee and patients will be included only after ethics committee approval. All data will be collected from procedures performed in actual clinical practice. Specific surgical interventions will not be performed for the purposes of this study, since this is an observational study.

After the surgeries, the patients will be followed up for one year. The patient's data will be collected on five visits scheduled for assessment of the outcomes of the study. (Baseline, T0, T90, T180 and T360).

The forecast for the study end is 24 months after the first inclusion.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients of both sexes will be included;
  • Regardless of race/color;
  • Aged between 18 and 70 years;
  • Who present partial or total tooth loss in a minimum period of three months;
  • Healthy edentulous region;
  • Good local and general health conditions, and psychological disposition;
  • To undergo common oral surgery procedures, under local anesthesia, in addition to undergoing surgical procedures using one of the implant systems under evaluation (Standard Internal Hexagon (HIS); Large Internal Hexagon (HIL); Flexcone (FC); Flexcone Mini (FCM) and Morse Internal Hexagon (HIM).

Exclusion criteria

  • Patients who need bone grafting;
  • Smokers who smoke 10 cigarettes/day or more;
  • Individuals who make continuous use of bisphosphonates and anticoagulants, alcoholics, and/or users of illicit drugs
  • Pregnant women;
  • Diabetics with uncontrolled glycemia and individuals
  • Patientes who were treated with radiotherapy.

Treatment and study plan

Primary outcomes

  1. Implant success rate 6 months after the procedure

    Time frame: 6 months

    Success = no radiolucency, no mobility, no recurrent peri-implant infection, no persistent pain

Secondary outcomes

  1. Adverse events related to medical device or procedure

    Time frame: Through study completion, an average of 2 years

    Record of events that may happen

Study contacts

Contact information is provided by the study sponsor or research team.

Marcelo C Goiato, PhD

CONTACT

[email protected]

+55 18 99752-4700

Ruan Barra, MSc

CONTACT

[email protected]

+55 34 8843-4741

Sponsors and collaborators

Lead sponsor

DSP Industrial Ltda

Industry

Registry information

Important dates

Study start
2023
Primary completion
2025
Study completion
2028
First posted
Aug 14, 2023
Registry last updated
Apr 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.